在一项长期回顾性研究中，常规使用 ATG Grafalon 后，严重急性和慢性移植物抗宿主病的发生率较低。
Low incidence of severe acute and chronic graft-versus-host disease in a long-term retrospective study with ATG Grafalon routine use.
机构信息
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Jihlavska 20, 62500, Brno, Czech Republic.
School of Medicine, Masaryk University, Brno, Czech Republic.
出版信息
Ann Hematol. 2023 Dec;102(12):3587-3591. doi: 10.1007/s00277-023-05479-w. Epub 2023 Oct 3.
Since 2006, combined graft-versus-host disease (GVHD) prophylaxis with ATG Grafalon has been our department's base of peri-transplant supportive care. This recent retrospective study included 398 patients who underwent their first allogeneic hematopoietic stem cell transplantation after receiving a defined dose of ATG Grafalon. Our observations recorded reduced incidence of severe acute and chronic GVHD without negative impact on overall survival in a nonselected group with standard and uniform GVHD prophylaxis.
自 2006 年以来，联合移植物抗宿主病（GVHD）预防与 ATG Grafalon 的治疗一直是我们科室移植后支持治疗的基础。本研究回顾性分析了 398 例接受特定剂量 ATG Grafalon 治疗后接受首次异基因造血干细胞移植的患者。我们的观察结果表明，在标准和统一的 GVHD 预防方案下，非选择性患者组严重急性和慢性 GVHD 的发生率降低，而总生存率没有受到负面影响。
Zotero 插件